Cardiovascular Devices Market Projected to Reach US$ 157.32 Billion by 2035, Supported by Expanding Clinical Research Activity Says Astute Analytica
View original at globenewswire.comCardiovascular Devices Market Projected to Reach US$ 157.32 Billion by 2035, Supported by Expanding Clinical Research Activity Says Astute Analytica Chicago, Jan…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
MANIFEST-17K study reported a 0% rate of esophageal damage and pericardial tamponade rate of just 0.36%
80% confidenceGlobal shipments of wearable health devices reached 440 million units in 2024, with 160 million units specifically designated as medical sensors for clinical monitoring
80% confidenceTotal surgical procedure volumes reached 18.9 million in 2024, with the United States and China accounting for 3.6 million and 3.5 million interventions, respectively
80% confidenceStroke caused 162,890 deaths in the US
80% confidenceFDA cleared 16 distinct breakthrough cardiovascular devices in the 12 months leading up to August 2024
80% confidenceThe US supported 4,300 operational cardiac catheterization labs in 2024, while the number of hybrid cath labs globally reached 2,400
80% confidenceFunding for AI-integrated cath lab solutions rose by 20% in 2024
80% confidenceUS market for smart wearable ECG monitors was valued at USD 586.91 million in 2024
80% confidenceMedical tourism options for TAVR in India were priced at approximately USD 14,500 in 2024
80% confidenceTotal US cardiovascular deaths hit 931,578 with age-adjusted death rate rose to 233.3 per 100,000
80% confidence127.9 million US adults had some form of cardiovascular disease in 2024
80% confidenceMedtronic's PulseSelect demonstrated an average skin-to-skin procedure time of just 36 minutes in 2024 with 98% of pulmonary veins remained isolated
80% confidenceNew clinical trial initiations surged by 68% in the decade ending 2024
80% confidenceBoston Scientific's Farapulse procedures finished in under 90 minutes in 90% of cases, while thermal ablation only achieved this speed in 60% of cases
80% confidenceThe global cardiovascular devices market size was valued at USD 74.58 billion in 2025 and is projected to hit the market valuation of USD 157.32 billion by 2035 at a CAGR of 7.70% during the forecast period 2026–2035
80% confidenceNorth America secured the largest geographical portion, contributing 45.68% of the revenue share in 2025
80% confidenceProjected global healthcare cost savings from wearable adoption estimated at USD 200 billion over the next 25 years
80% confidenceChina accounted for 22.26% of the global cardiovascular disease burden
80% confidenceThe therapeutics & surgical devices category held a commanding position, accounting for a 77.5% revenue share in 2025
80% confidenceVascular device investment reaching USD 759 million and cardiovascular venture investment stabilizing at USD 542 million in 2024
80% confidenceFDA listed 1,176 devices in its Breakthrough Device Program as of August 2024, with 243 designations specifically allocated to cardiovascular innovations
80% confidence92% of US smartwatch users utilize their device primarily for health tracking, with 37% specifically monitoring heart metrics
80% confidence45% of global cath lab equipment exports originating from US manufacturers in 2024
80% confidenceAverage cost for a TAVR procedure in 2024 ranged from USD 52,176 in Chicago to USD 81,889 in California
80% confidenceUK cardiac waiting list swelling to 421,433 patients by May 2024 and Canadian wait times reaching 194 days
80% confidenceTriClip patients were 28% less likely to be hospitalized for heart failure and 90% of TriClip patients saw regurgitation reduction
80% confidenceA 2025 analysis identified 51 major cardiovascular clinical trials published between 2019 and 2024, enrolling a total of 292,985 patients
80% confidenceWeekly procedure rates averaging 16,200 cases throughout 2024 for pulsed field ablation
80% confidence46% of US counties operate without a single practicing cardiologist, while 86% of rural counties lack access entirely
80% confidenceAs of December 2025, over 2,000 cardiovascular drugs and device-delivery therapies were in active development
80% confidence
Data points we hold from this source
| U.S. Food and Drug Administration · cardiology ai algorithms total | 116 algorithms |
| U.S. Food and Drug Administration · ai algorithms cleared may 2025 | 39 algorithms |
| U.S. Food and Drug Administration · cleared breakthrough cvd devices 12mo | 16 devices |
| U.S. Food and Drug Administration · breakthrough cardiovascular devices | 243 devices |
| U.S. Food and Drug Administration · breakthrough devices total | 1176 devices |